--- title: 'Senior / Executive Medical Director, Clinical Development (Oncology) at Iambic Therapeutics, Inc' canonical: 'https://feeny.ai/job/senior-executive-medical-director-clinical-development-oncology-iambic-gzg6q1pt9sky' type: 'job' last_seen: '2026-09-09' --- # Senior / Executive Medical Director, Clinical Development (Oncology) at Iambic Therapeutics, Inc - **Company:** Iambic Therapeutics, Inc - **Location:** San Diego, CA - **Employment:** full-time - **Work type:** onsite - **Posted:** 2026-08-07 - **Last confirmed live:** 2026-09-09 - **Apply:** https://jobs.ashbyhq.com/iambic-therapeutics/df3de5b0-b4df-4421-be9b-3ac7bb8f5554 ## Job description ## JOB SUMMARY We are seeking a Senior or Executive Medical Director to provide medical and clinical development leadership for our early-stage oncology portfolio. This individual will own the clinical strategy and execution for one or more assets from IND-enabling activities through first-in-human and early efficacy studies. You will serve as the clinical and scientific lead on cross-functional program teams, working closely with our discovery, translational, regulatory, and clinical operations groups — and directly alongside our AI/ML platform teams — to translate novel candidates into well-designed clinical programs. This position will be based in our San Diego Headquarters. Title and scope will be calibrated to the successful candidate's experience. ## KEY RESPONSIBILITIES - Serve as the clinical/medical lead for early-stage oncology programs, owning the clinical development strategy from IND through Phase 1 and early proof-of-concept. - Author and drive the clinical components of IND submissions, including protocols, investigator's brochures, and clinical sections of regulatory documents; support and participate in health authority interactions (e.g., pre-IND, EOP1). - Design first-in-human and early-phase oncology trials, including dose-escalation and dose-optimization strategies, biomarker and translational plans, and eligibility criteria. - Provide ongoing medical monitoring and safety oversight for active trials, including review of emerging safety data, dose decisions, and management of study conduct in partnership with Clinical Operations and Pharmacovigilance. - Partner with translational science and the AI/ML platform teams to define patient selection strategies, pharmacodynamic endpoints, and data-driven development hypotheses. - Engage key opinion leaders, investigators, and study sites; represent programs to internal governance, partners, and, as appropriate, external stakeholders. - Collaborate cross-functionally with Regulatory Affairs, CMC, Clinical Operations, Biostatistics, and Program Management to keep programs on strategy and on timeline. - Contribute to portfolio-level decisions, candidate selection input, and business development / due diligence as needed. ## QUALIFICATIONS - M.D. or D.O. (or international equivalent); board eligibility/certification in hematology/oncology or medical oncology strongly preferred; exceptional candidates with PharmD and relevant oncology and clinical experience will be considered - Meaningful drug-development experience in biotech or pharma. We anticipate roughly 5+ years for a Senior Medical Director and 8–10+ years for an Executive Medical Director; strong candidates across this range are encouraged to apply. - Direct, hands-on experience authoring and executing IND submissions. - Direct experience designing and running Phase 1 / early-phase oncology clinical trials. - Demonstrated experience with oncology assets and a strong understanding of the oncology therapeutic and drug-development landscape. - Working knowledge of GCP, ICH guidelines, and the global regulatory environment for oncology development. ## PREFERRED QUALIFICATIONS - Experience with small-molecule oncology programs and targeted therapies. - Experience taking a program from candidate nomination or IND through clinical proof-of-concept. - Comfort working in a fast-paced, data-rich, technology-forward environment and collaborating with computational and platform teams. - Prior experience presenting to health authorities and/or supporting BD due diligence ## ABOUT IAMBIC THERAPEUTICS Iambic is a clinical-stage life-science and technology company developing novel medicines using its AI-driven discovery and development platform. Based in San Diego and founded in 2020, Iambic has assembled a world-class team that unites pioneering AI experts and experienced drug hunters. The Iambic platform has demonstrated delivery of new drug candidates to human clinical trials with unprecedented speed and across multiple target classes and mechanisms of action. Iambic is advancing a pipeline of potential best-in-class and first-in-class clinical assets, both internally and in partnership, to address urgent unmet patient need. Learn more about the Iambic team, platform, pipeline, and partnerships at iambic.ai http://iambic.ai. ## MISSION & CORE VALUES Our mission is to deliver better medicines through innovations in AI-based discovery technologies. The culture and work at Iambic Therapeutics are profoundly strengthened by the diversity of our people and our differences in background, culture, national origin, religion, sexual orientation, and life experiences. We are committed to building an inclusive environment where a diverse group of talented humans work together to discover therapeutics and create technologies. ## PAY AND BENEFITS We offer industry leading competitive pay, company paid healthcare, flexible spending accounts, voluntary life insurance, 401K matching, and uncapped vacation to our team. We are in a brand-new state-of-the art facility in beautiful San Diego with an onsite gym, dining, and easy access to great places to live and play. ## About Iambic Therapeutics, Inc ## Company Overview - **One-liner**: Iambic Therapeutics is a clinical‑stage biotechnology company that uses an AI‑driven platform to discover and develop novel small‑molecule medicines for oncology and other diseases. - **Entity Type**: Private (late‑stage venture‑backed) - **Headquarters**: San Diego, California, United States - **Founded**: 2020 - **Founders**: Not explicitly named in available sources; leadership includes a Co‑Founder & CEO and a Co‑Founder & CTO. ## Core Business - **Primary industries**: Biotechnology, AI‑powered drug discovery, oncology therapeutics - **Target customers**: B2B partnerships with pharmaceutical companies (e.g., Bayer) and, ultimately, patients through a wholly‑owned pipeline of clinical‑stage candidates - **Mission**: *“Better technology for better medicines”* – using machine learning and automation to transform the creation of new therapeutics ## Products & Services - **Enchant Platform**: A multi‑modal transformer AI that breaks down data barriers between preclinical and clinical R&D, enabling rapid molecular design. - **NeuralPLexer**: A co‑folding AI technology that predicts protein‑ligand structures to guide drug design. - **Automated High‑Throughput Experimentation**: AI‑driven robotics that generate new biological data from novel molecular designs on a weekly cadence. - **IAM1363** (HER2 inhibitor): A highly selective, brain‑penetrant tyrosine kinase inhibitor for HER2‑driven cancers; currently in Phase 1b clinical studies. - **IAM‑C1** (CDK2/4 dual inhibitor): A potential first‑in‑class selective inhibitor for HR+/HER2‑ metastatic breast cancer (preclinical). - **IAM‑K1** (KIF18A inhibitor): A potential best‑in‑class allosteric inhibitor for triple‑negative breast cancer, ovarian cancer, and other solid tumors (preclinical). - **Undisclosed programs**: Additional wholly‑owned candidates across multiple target classes and mechanisms. ## Market Standing - **Valuation**: Not publicly disclosed - **Key Metric**: **Total funding** – $330.8 M (including a $100 M Series B in Oct 2023, a $50 M Series B extension in Apr 2024 led by EXOR N.V. and Mubadala Capital, and a $127.8 M venture round in Nov 2025) - **Notable Investors/Partners**: EXOR N.V., Mubadala Capital, Nexus Venture, Bayer (collaboration in AI drug discovery), and a Scientific Advisory Board including Nobel Laureate Frances Arnold (Caltech) - **Growth Signals**: - Headcount of **117** (64.5 % year‑over‑year growth) - Active job postings: **18** (+200 % quarterly, +50 % yearly) - Pipeline advanced from program launch to IND in **2 years** (vs. 6‑year industry average for IAM1363) - Broad platform applicability demonstrated across orthosteric, allosteric, and protein‑protein interaction modalities ## Competitive Advantages - **Speed**: AI‑driven platform can deliver development candidates to clinical trials in roughly one‑third the industry average time. - **Selectivity & Differentiated Profiles**: IAM1363 shows > 5000‑fold selectivity against EGFR, avoiding EGFR‑driven toxicity; IAM‑C1 targets CDK2/4 with a novel selectivity profile. - **Broad Platform Applicability**: Platform has produced leads across diverse protein classes and mechanisms (orthosteric, allosteric, PPI modulators). - **Integration of AI and Drug Hunting**: Tightly integrated team of AI experts and seasoned drug hunters, with a culture of “audacity” that tackles hard chemistry problems. ## Strategic Focus - Advancing the clinical pipeline: IAM1363 Phase 1b, preparing IAM‑C1 and IAM‑K1 for IND‑enabling studies. - Expanding platform partnerships (e.g., Bayer collaboration). - Scaling the organization: actively hiring in ML science, computational chemistry, medicinal chemistry, and clinical operations. - Exploring new therapeutic areas and target classes through the Enchant and NeuralPLexer technologies. ## Why Work Here - **Culture**: Values of **Respect**, **Collaboration**, and **Audacity** – cross‑functional teamwork with resilience and optimism; a flat, high‑trust environment. - **Work Model**: Based in La Jolla/San Diego, CA; the company emphasizes on‑site collaboration for drug‑discovery and lab‑based roles; remote/hybrid policy not explicitly stated. - **Team Growth**: Rapidly scaling (headcount +64 % YoY) with a strong pipeline of open roles in ML, computational chemistry, drug product development, and clinical operations. - **Cutting‑Edge Work**: Opportunity to work at the intersection of frontier AI (large multimodal models, agentic data pipelines) and real‑world drug discovery that reaches patients. - **Leadership & Mentorship**: Advisory board includes Nobel laureate and former NVIDIA AI director; close integration of AI and biology. ## Sources 1. [iambic.ai](https://www.iambic.ai/) – Homepage, platform, and corporate overview 2. [iambic.ai/about](https://www.iambic.ai/about) – Leadership, advisory board, investors 3. [iambic.ai/pipeline](https://www.iambic.ai/pipeline) – Pipeline details (IAM1363, IAM‑C1, IAM‑K1) 4. [iambic.ai/careers](https://www.iambic.ai/careers) – Careers page, values, open positions 5. [linkedin.com/company/iambic-ai](https://www.linkedin.com/company/iambic-ai) – Company stats (headcount 117, $3.4M revenue, $330.8M funding, funding rounds, employee growth) ## Other roles at Iambic Therapeutics, Inc - [Sr Manager, FP&A - Discovery R&D](https://feeny.ai/job/sr-manager-fp-a-discovery-r-d-iambic-therapeutics-inc-san-diego-sznt8xkbx741) — San Diego, CA - [Director/Senior Director, Immunology](https://feeny.ai/job/director-senior-director-immunology-iambic-therapeutics-inc-san-diego-pc8aedpavc67) — San Diego, CA - [Software Engineer — Agentic data pipelines](https://feeny.ai/job/software-engineer-agentic-data-pipelines-iambic-therapeutics-inc-united-states-z1afztyyenvn) — United States - [Principal Medical Writer](https://feeny.ai/job/principal-medical-writer-iambic-therapeutics-inc-united-states-p7p8wv9kdmyd) — United States - [Sr Manager, Quality Systems & Compliance](https://feeny.ai/job/sr-manager-quality-systems-compliance-iambic-therapeutics-inc-united-states-vsh166q5vj7e) — United States - [Research Scientist I/II, Bioanalytical Sciences & Assay Development](https://feeny.ai/job/research-scientist-i-ii-bioanalytical-sciences-assay-development-iambic-z1xnw171hxqv) — San Diego, CA - [Machine Learning Scientist – Clinical Prediction](https://feeny.ai/job/machine-learning-scientist-clinical-prediction-iambic-therapeutics-inc-boston-r8b4amskssr5) — Boston, MA - [Machine Learning Scientist — Large Multimodal Models (Post-Training)](https://feeny.ai/job/machine-learning-scientist-large-multimodal-models-post-training-iambic-7rzbhfe24hz9) — United Kingdom - [Machine Learning Scientist — Large Multimodal Models (Post-Training)](https://feeny.ai/job/machine-learning-scientist-large-multimodal-models-post-training-iambic-tq20zrdrpft4) — Boston, MA - [Senior / Executive Director, Analytical Development CMC](https://feeny.ai/job/senior-executive-director-analytical-development-cmc-iambic-therapeutics-inc-xc2n3pav2s88) — United States